Pharmacogenomics: Candidate gene identification, functional validation and mechanisms

Human Molecular Genetics

Volumn 17, Issue R2, 2008, Pages

  Wang, Liewei ^a   Weinshilboum, Richard M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC VARIABILITY; GENETICS; HUMAN; HUMAN GENOME; METHODOLOGY; PHARMACOGENETICS; REVIEW; STANDARD;

GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC VARIATION; GENOME, HUMAN; HUMANS; PHARMACOGENETICS;

EID: 58149352685     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddn270     Document Type: Article

References (40)

1. Weinshilboum, R. (2003) Inheritance and drug response. N. Engl. J. Med., 348, 529-537.
2. Weinshilboum, R.M. and Wang, L. (2006) Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu. Rev. Genomics Hum. Genet., 7, 223-245.
3. Wang, L. and Weinshilboum, R. (2006) Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene, 25, 1629-1638.
4. Innocenti, F. and Ratain, M.J. (2004) 'Irinogenetics' and UGT1A: from genotypes to haplotypes. Clin. Pharmacol. Ther., 75, 495-500.
5. Aithal, G.P., Day, C.P., Kesteven, P.J. and Daly, A.K. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 353, 717-719.
6. Goetz, M.P., Knox, S.K., Suman, V.J., Rae, J.M., Safgren, S.L., Ames, M.M., Visscher, D.W., Reynolds, C., Couch, F.J., Lingle, W.L. et al. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat., 101, 113-121.
7. Weinshilboum, R. (2008) Pharmacogenomics of endocrine therapy in breast cancer. In Bernstein, L.M. and Santen, R.J. (eds), Innovative Endocrinology of Cancer, Chapter 14. Landes Biosciences, Austin, TX, pp. 220-231.
8. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, Novartis Institutes of BioMedical Research Saxena, R., Voight, B.F., Lyssenko, V., Burtt, N.P., de Bakker, P.I., Chen, H., Roix, J.J. et al. (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science, 316, 1331-1336.
9. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D., Thompson, D., Ballinger, D.G., Struewing, J.P., Morrison, J., Field, H., Luben, R. et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087-1093.
10. Zeggini, E., Weedon, M.N., Lindgren, C.M., Frayling, T.M., Elliott, K.S., Lango, H., Timpson, N.J., Perry, J., Rayner, N.W., Freathy, R.M. et al. (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science, 316, 1336-1341.
11. Scott, L.J., Mohlke, K.L., Bonnycastle, L.L., Willer, C.J., Li, Y., Duren, W.L., Erdos, M.R., Stringham, H.M., Chines, P.S., Jackson, A.U. et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science, 316, 1341-1345.
12. Kathiresan, S., Melander, O., Anevski, D., Guiducci, C., Burtt, N.P., Roos, C., Hirschhorn, J.N., Berglund, G., Hedblad, B., Groop, L. et al. (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. N. Engl. J. Med., 358, 1240-1249.
13. Thompson, P.D., Clarkson, P. and Karas, R.H. (2003) Statin-associated myopathy. J. Am. Med. Assoc., 289, 1681-1690.
14. The SEARCH Collaborative Group (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. The SEARCH Collaborative Group. N. Engl. J. Med., 359, 789-799.
15. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 highrisk individuals: a randomised placebo-controlled trial. Lancet, 360, 7-22.
16. Shoemaker, R.H. (2006) The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer, 6, 813-823.
17. Weinstein, J.N. and Pommier, Y. (2003) Transcriptomic analysis of the NCI-60 cancer cell lines. C. R. Biol., 326, 909-920.
18. Weinstein, J.N. (2008) Biochemistry. A postgenomic visual icon. Science, 319, 1772-1773.
19. The International HapMap Consortium (2003) The international HapMap project. Nature, 426, 789-796.
20. International HapMap Consortium (2004) Integrating ethics and science in the international HapMap project. Nat. Rev. Genet., 5, 467-475.
21. International HapMap Consortium (2005) A haplotype map of the human genome. Nature, 437, 1299-1320.
22. Frazer, K.A., Ballinger, D.G., Cox, D.R., Hinds, D.A., Stuve, L.L., Gibbs, R.A., Belmont, J.W., Boudreau, A., Hardenbol, P., Leal, S.M. et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature, 449, 851-861.
23. Thorisson, G.A., Smith, A.V., Krishnan, L. and Stein, L.D. (2005) The international HapMap project web site. Genome Res., 15, 1592-1593.
24. Redon, R., Ishikawa, S., Fitch, K.R., Feuk, L., Perry, G.H., Andrews, T.D., Fiegler, H., Shapero, M.H., Carson, A.R., Chen, W. et al. (2006) Global variation in copy number in the human genome. Nature, 444, 444-454.
25. Stranger, B.E., Forrest, M.S., Dunning, M., Ingle, C.E., Beazley, C., Thorne, N., Redon, R., Bird, C.P., de Grassi, A., Lee, C. et al. (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science, 315, 848-853.
26. Spielman, R.S., Bastone, L.A., Burdick, J.T., Morley, M., Ewens, W.J. and Cheung, V.G. (2007) Common genetic variants account for differences in gene expression among ethnic groups. Nat. Genet., 39, 226-231.
27. Storey, J.D., Madeoy, J., Strout, J.L., Wurfel, M., Ronald, J. and Akey, J.M. (2007) Gene-expression variation within and among human populations. Am. J. Hum. Genet., 80, 502-509.
28. Stranger, B.E., Nica, A.C., Forrest, M.S., Dimas, A., Bird, C.P., Beazley, C., Ingle, C.E., Dunning, M., Flicek, P., Koller, D. et al. (2007) Population genomics of human gene expression. Nat. Genet., 39, 1217-1224.
29. Huang, R.S., Duan, S., Bleibel, W.K., Kistner, E.O., Zhang, W., Clark, T.A., Chen, T.X., Schweitzer, A.C., Blume, J.E., Cox, N.J. et al. (2007) A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc. Natl. Acad. Sci. USA, 104, 9758-9763.
30. Li, L., Fridley, B.L., Kalari, K.R., Jenkins, G.D., Batzler, A., Safgren, S.L., Hildebrandt, M.A.T., Ames, M.M., Schaid, D.J. and Wang, L. (2008) Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res., 68, 7050-7088.
31. Huang, R.S., Duan, S., Kistner, E.O., Bleibel, W.K., Delaney, S.M., Fackenthal, D.L., Das, S. and Dolan, M.E. (2008) Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res., 68, 3161-3168.
32. Shukla, S.J., Duan, S., Badner, J.A., Wu, X. and Dolan, M.E. (2008) Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet. Genomics, 18, 253-262.
33. Duan, S., Bleibel, W.K., Huang, R.S., Shukla, S.J., Wu, X., Badner, J.A. and Dolan, M.E. (2007) Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res., 67, 5425-5433.
34. Cheung, V.G., Conlin, L.K., Weber, T.M., Arcaro, M., Jen, K.Y., Morley, M. and Spielman, R.S. (2003) Natural variation in human gene expression assessed in lymphoblastoid cells. Nat. Genet., 33, 422-425.
35. Liu, M.T., Chen, Y.R., Chen, S.C., Hu, C.Y., Lin, C.S., Chang, Y.T., Wang, W.B. and Chen, J.Y. (2004) Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene, 23, 2531-2539.
36. Feng, W.H., Hong, G., Delecluse, H.J. and Kenney, S.C. (2004) Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J. Virol., 78, 1893-1902.
37. Tai, H.L., Fessing, M.Y., Bonten, E.J., Yanishevsky, Y., d'Azzo, A., Krynetski, E.Y. and Evans, W.E. (1999) Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT_2, TPMT_3A, TPMT_3B or TPMT_3C. Pharmacogenetics, 9, 641-650.
38. Wang, L., Nguyen, T.V., McLaughlin, R.W., Sikkink, L.A., Ramirez-Alvarado, M. and Weinshilboum, R.M. (2005) Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc. Natl. Acad. Sci. USA, 102, 9394-9399.
39. Wang, L., Sullivan, W., Toft, D. and Weinshilboum, R. (2003) Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics, 13, 555-564.
40. Li, F., Wang, L., Burgess, R.J. and Weinshilboum, R.M. (2008) Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. Pharmacogenet Genomics (in press).